PharmAthene Inc. (PIP) Achieves Progress in Second Generation Anthrax Vaccine
Today, PharmAthene, Inc. announced that it has achieved significant progress in developing its second generation anthrax vaccine, SparVax™ with the completion of a 1,500 liter engineering production run. This achievement follows the completion of the initial technology transfer at the 100 liter scale and 36 months of stability. Dr. Thomas Fuerst, Executive Vice President and Chief Scientific Officer, remarked, "PharmAthene has developed a robust manufacturing process for SparVax™ with the capability to produce more than 200 million rPA vaccine equivalent doses of bulk drug substance at the 50 mcg dose range on an annual basis. The use of recombinant vaccine…